SJS Investment Consulting Inc. Buys 323 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

SJS Investment Consulting Inc. raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6,460.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 328 shares of the medical equipment provider’s stock after acquiring an additional 323 shares during the period. SJS Investment Consulting Inc.’s holdings in Lantheus were worth $28,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. National Bank of Canada FI grew its position in Lantheus by 35.7% in the first quarter. National Bank of Canada FI now owns 445 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 117 shares during the period. AlphaMark Advisors LLC grew its holdings in shares of Lantheus by 456.3% during the first quarter. AlphaMark Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 365 shares during the last quarter. Macquarie Group Ltd. grew its holdings in shares of Lantheus by 21.7% during the first quarter. Macquarie Group Ltd. now owns 605 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 108 shares during the last quarter. Clearstead Advisors LLC bought a new stake in shares of Lantheus during the first quarter worth $52,000. Finally, Castleview Partners LLC grew its holdings in shares of Lantheus by 12,842.9% during the first quarter. Castleview Partners LLC now owns 906 shares of the medical equipment provider’s stock worth $75,000 after purchasing an additional 899 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

LNTH has been the topic of several research analyst reports. Truist Financial restated a “buy” rating and set a $125.00 target price on shares of Lantheus in a report on Friday. TheStreet upgraded Lantheus from a “c” rating to a “b-” rating in a report on Wednesday, August 9th. Finally, StockNews.com initiated coverage on Lantheus in a report on Thursday, August 17th. They issued a “buy” rating on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $121.83.

Insider Activity

In other news, President Paul Blanchfield sold 1,500 shares of Lantheus stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $65.19, for a total transaction of $97,785.00. Following the transaction, the president now owns 90,475 shares in the company, valued at approximately $5,898,065.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Lantheus news, CAO Andrea Sabens sold 1,752 shares of the business’s stock in a transaction that occurred on Wednesday, July 19th. The stock was sold at an average price of $90.87, for a total transaction of $159,204.24. Following the transaction, the chief accounting officer now owns 59,767 shares of the company’s stock, valued at approximately $5,431,027.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Paul Blanchfield sold 1,500 shares of the business’s stock in a transaction that occurred on Friday, August 18th. The stock was sold at an average price of $65.19, for a total value of $97,785.00. Following the transaction, the president now directly owns 90,475 shares in the company, valued at approximately $5,898,065.25. The disclosure for this sale can be found here. Insiders have sold 19,315 shares of company stock worth $1,353,773 in the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Lantheus Trading Down 1.7 %

LNTH traded down $1.09 during midday trading on Tuesday, reaching $63.01. 417,714 shares of the company were exchanged, compared to its average volume of 1,014,151. Lantheus Holdings, Inc. has a one year low of $47.46 and a one year high of $100.85. The company has a debt-to-equity ratio of 1.01, a quick ratio of 4.55 and a current ratio of 4.88. The stock has a market capitalization of $4.31 billion, a P/E ratio of 156.34 and a beta of 0.68. The stock’s 50-day simple moving average is $73.57 and its 200 day simple moving average is $81.84.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, August 3rd. The medical equipment provider reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.17. Lantheus had a return on equity of 67.18% and a net margin of 2.97%. The business had revenue of $321.70 million for the quarter, compared to analysts’ expectations of $306.48 million. As a group, analysts forecast that Lantheus Holdings, Inc. will post 5.19 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.